Mazzetti A - Search Results

1

Long-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris.

Eichenfield LF, Hebert AA, Gold LS, Cartwright M, Moro L, Han J, Squittieri N, Mazzetti A. Eichenfield LF, et al. Among authors: mazzetti a. J Drugs Dermatol. 2023 Aug 1;22(8):810-816. doi: 10.36849/jdd.7592. J Drugs Dermatol. 2023. PMID: 37556524 Clinical Trial.

2

Ambroxol for prophylaxis and treatment of bronchopulmonary complications after chest surgery.

Romanini BM, Sandri MG, Tosi M, Mezzetti M, Mazzetti A. Romanini BM, et al. Among authors: mazzetti a. Int J Clin Pharmacol Res. 1986;6(2):123-7. Int J Clin Pharmacol Res. 1986. PMID: 3522443 Clinical Trial.

3

Cortexolone 17α-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro.

Rosette C, Rosette N, Mazzetti A, Moro L, Gerloni M. Rosette C, et al. Among authors: mazzetti a. J Drugs Dermatol. 2019 Feb 1;18(2):197-201. J Drugs Dermatol. 2019. PMID: 30811143

4

Cortexolone 17α-propionate (Clascoterone) Is a Novel Androgen Receptor Antagonist that Inhibits Production of Lipids and Inflammatory Cytokines from Sebocytes In Vitro.

Rosette C, Agan FJ, Mazzetti A, Moro L, Gerloni M. Rosette C, et al. Among authors: mazzetti a. J Drugs Dermatol. 2019 May 1;18(5):412-418. J Drugs Dermatol. 2019. PMID: 31141847

5

Pharmacokinetic Profile, Safety, and Tolerability of Clascoterone (Cortexolone 17-alpha propionate, CB-03-01) Topical Cream, 1% in Subjects With Acne Vulgaris: An Open-Label Phase 2a Study.

Mazzetti A, Moro L, Gerloni M, Cartwright M. Mazzetti A, et al. J Drugs Dermatol. 2019 Jun 1;18(6):563. J Drugs Dermatol. 2019. PMID: 31251549 Clinical Trial.

6

A Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects With Facial Acne.

Mazzetti A, Moro L, Gerloni M, Cartwright M. Mazzetti A, et al. J Drugs Dermatol. 2019 Jun 1;18(6):570. J Drugs Dermatol. 2019. PMID: 31251550 Clinical Trial.

7

Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials.

Hebert A, Thiboutot D, Stein Gold L, Cartwright M, Gerloni M, Fragasso E, Mazzetti A. Hebert A, et al. Among authors: mazzetti a. JAMA Dermatol. 2020 Jun 1;156(6):621-630. doi: 10.1001/jamadermatol.2020.0465. JAMA Dermatol. 2020. PMID: 32320027 Free PMC article. Clinical Trial.

8

Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris.

Eichenfield L, Hebert A, Gold LS, Cartwright M, Fragasso E, Moro L, Mazzetti A. Eichenfield L, et al. Among authors: mazzetti a. J Am Acad Dermatol. 2020 Aug;83(2):477-485. doi: 10.1016/j.jaad.2020.04.087. Epub 2020 Apr 26. J Am Acad Dermatol. 2020. PMID: 32348828 Free article. Clinical Trial.

9

Potential Role for Topical Antiandrogens in the Management of Acne Among Patients Receiving Masculinizing Hormone Therapy-Reply.

Thiboutot D, Cartwright M, Mazzetti A. Thiboutot D, et al. Among authors: mazzetti a. JAMA Dermatol. 2020 Dec 1;156(12):1381. doi: 10.1001/jamadermatol.2020.3341. JAMA Dermatol. 2020. PMID: 33146696 No abstract available.

10

Efficacy and Safety of 1% Clascoterone Cream in Patients Aged > 12 Years With Acne Vulgaris.

Hebert A, Eichenfield L, Thiboutot D, Stein Gold L, Vassileva S, Mihaylova Y, Cartwright M, Moro L, Fragasso E, Han J, Squittieri N, Mazzetti A. Hebert A, et al. Among authors: mazzetti a. J Drugs Dermatol. 2023 Feb 1;22(2):174-181. doi: 10.36849/JDD.7000. J Drugs Dermatol. 2023. PMID: 36745367 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters